Health Care [ 9/12 ] | Health Care Equipment & Supplies [ 56/74 ]
NASDAQ | Common Stock
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally.
The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
In addition, the company offers Accelerate Arc system, an instrument and associated one-time-use test kit that automates the clean-up and concentration of microbial cells from positive blood culture samples.
Further, it develops Accelerate WAVE system, which performs AST directly from positive blood culture bottles and bacterial isolate colonies to report minimum inhibitory concentrations.
The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.
Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 26, 25 | -0.37 Increased by +54.32% | -0.50 Increased by +26.00% |
| Nov 7, 24 | -0.59 Decreased by -521.43% | -0.47 Decreased by -25.53% |
| Aug 8, 24 | -0.53 Increased by +59.54% | -0.55 Increased by +3.64% |
| May 8, 24 | -0.88 Decreased by -417.65% | -0.72 Decreased by -22.22% |
| Jan 7, 24 | -0.81 Decreased by -478.57% | -0.62 Decreased by -30.65% |
| Nov 9, 23 | 0.14 Increased by +177.78% | -1.07 Increased by +113.08% |
| Aug 10, 23 | -1.31 Decreased by -469.57% | -1.40 Increased by +6.43% |
| May 11, 23 | -0.17 Increased by +19.05% | -0.14 Decreased by -21.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 2.82 M Decreased by -3.59% | -9.59 M Increased by +32.61% | Decreased by -340.52% Increased by +30.10% |
| Dec 31, 24 | 2.82 M Decreased by -6.13% | -9.59 M Increased by +26.24% | Decreased by -340.52% Increased by +21.42% |
| Sep 30, 24 | 2.98 M Decreased by -9.82% | -14.64 M Decreased by -1.71 K% | Decreased by -492.07% Decreased by -1.88 K% |
| Jun 30, 24 | 2.99 M Increased by +2.23% | -11.59 M Increased by +55.40% | Decreased by -388.08% Increased by +56.37% |
| Mar 31, 24 | 2.92 M Increased by +3.88% | -14.23 M Increased by +20.71% | Decreased by -487.16% Increased by +23.67% |
| Dec 31, 23 | 3.00 M Increased by +0.94% | -13.00 M Increased by +12.16% | Decreased by -433.33% Increased by +12.98% |
| Sep 30, 23 | 3.30 M Increased by +11.45% | 910.00 K Increased by +105.47% | Increased by +27.58% Increased by +104.91% |
| Jun 30, 23 | 2.92 M Decreased by -24.35% | -25.98 M Decreased by -47.47% | Decreased by -889.42% Decreased by -94.93% |